65898-66-0

Upstream product

• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 78-95-5 chloroacetone 
• 61771-77-5 ethyl 2-oxo-1-(2-oxopropyl)cyclopentane-1-carboxylate 
• 74766-18-0 1-(2-Ethoxy-allyl)-2-oxo-cyclopentanecarboxylic acid ethyl ester 
• 77320-46-8 2-oxo-1-prop-2-ynylcyclopentanecarboxylic acid ethyl ester 
• 126361-52-2 methoxycarbonylhydrazono-2 (ethoxycarbonyl-1 oxo-2 cyclopentyl)-3 propylphosphonate de diethyle 
• 110271-65-3 (ethoxycarbonyl-1 oxo-2 cyclopentyl)-3 oxo-2 propylphosphonate de diethyle 

Downstream Products

• 1461686-03-2 ethyl 3-(1-((2S,3aR,6aR)-3a-((1S,4S)-5-(4-(trifluoromethyl)pyridin-2-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)octahydropentalen-2-yl)piperidin-4-yl)benzoate 
• 1461685-94-8 3-{1-[(2S,3aR,6aR)-3a-({(1S,4S)-5-[4-(trifluoromethyl)pyridin-2-yl]-2,5-diazabicyclo[2.2.1]hept-2-yl}carbonyl)octahydropentalen-2-yl]piperidin-4-yl}benzoic acid 
• 1461686-07-6 3-{1-[(2R,3aR,6aR)-3a-({(1S,4S)-5-[4-(trifluoromethyl)pyridin-2-yl]-2,5-diazabicyclo[2.2.1]hept-2-yl}carbonyl)octahydropentalen-2-yl]piperidin-4-yl}benzoic acid 

Relevant academic research and scientific papers

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

CHEMOKINE RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using

CHEMOKINE RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein R1, R2, and R3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using

Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists

Novel CCR2 antagonists with a novel 2-aminooctahydrocyclopentalene-3a- carboxamide scaffold were designed. SAR studies led to a series of potent compounds. For example, compound 51 had a good PK profile in both dog and monkey, and exhibited excellent efficacy when dosed orally in an inflammation model in hCCR2 KI mice. In addition, an asymmetric synthesis to the core structures was developed.

CHLORO-1 ET CHLORO-3 METHOXYCARBONYLHYDRAZONO-2 PROPYLPHOSPHONATES: REACTIFS D'ALKYLATION D'ENOLATES DE CETONES. ACCES A DES PHOSPHONATES PYRROLIQUES ET A DES β,ε DICETOPHOSPHONATES PRECURSEURS DE CYCLOPENTENONES

The reactivity of keto enolates with 1-chloro and 3-chloro-2-methoxycarbonylhydrazono-propylphosphonates 1 and 2 is studied.It is shown that those enolates react with the chlorohydrazone 1 to give 3-diethoxyphosphonopyrroles 5 under a mechanistic pathway

Mn(III)-PROMOTED ANNULATION OF ENOL ETHERS AND ESTERS TO FUSED OR SPIRO 2-CYCLOPENTENONES

Manganese(III)-promoted addition of various 1,3-dicarbonyl compounds to enol ethers or terminal enol esters, followed by hydrolysis of the resulting adducts and base catalyzed aldol cyclization provides an effective process for the synthesis of a wide ran